The Pathology Core Facility of the Robert H. Lurie Comprehensive Cancer Center provides pathological analysis and specimen procurement, processing and distribution services to the NU research community. Pathological analysis in the past was mostly limited to routine tissue processing, staining and a limited panel of immunohistochemical stains. Today, pathological analysis in cancer research involves more sophisticated testing, including high-throughput tissue microarray generation, novel immunohistochemistry, in situ hybridization, or digital imaging analysis for the objective assessment of tissue based assays. Similarly, specimen procurement, processing and distribution are increasingly more sophisticated today. Cancer researchers now require technologies such as DNA/RNA/mRNA extraction, generation of cell monolayers from body fluids, laser capture microdissection, isolation of circulating tumor cells, and other technologies to address cancer-related questions. An exciting development in cancer care in the past few years is the use of targeted therapies and the sub-stratification of patients into more precise treatment groups. Examples include her2/neu testing by FISH or IHC in breast cancer, thymidylate synthase testing in colon cancer, MSI testing in colon cancer, c-kit testing in a variety of tumors, pharmacogenomics and others. Other examples of these """"""""cutting-edge"""""""" approaches to cancer research are presented throughout this grant. The PCF is fortunate to be at the forefront of these exciting developments in cancer care in its capacity as the Reference Laboratory for the Eastern Cooperative Oncology Group. Continued funding of the PCF infrastructure will allow it to continue to meet the growing and increasingly complex needs of cancer patients and cancer researchers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA060553-18S5
Application #
8546488
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-09-18
Project End
2013-07-31
Budget Start
2012-09-18
Budget End
2013-07-31
Support Year
18
Fiscal Year
2012
Total Cost
$76,389
Indirect Cost
$12,131
Name
Northwestern University at Chicago
Department
Type
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Moinpour, Carol M; Donaldson, Gary W; Davis, Kimberly M et al. (2017) The challenge of measuring intra-individual change in fatigue during cancer treatment. Qual Life Res 26:259-271
Lamar, Tyra; Vanoye, Carlos G; Calhoun, Jeffrey et al. (2017) SCN3A deficiency associated with increased seizure susceptibility. Neurobiol Dis 102:38-48
Yu, Dou; Khan, Omar F; SuvĂ , Mario L et al. (2017) Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proc Natl Acad Sci U S A 114:E6147-E6156
Mohr, David C; Tomasino, Kathryn Noth; Lattie, Emily G et al. (2017) IntelliCare: An Eclectic, Skills-Based App Suite for the Treatment of Depression and Anxiety. J Med Internet Res 19:e10
Apple, Alexandra C; Ryals, Anthony J; Alpert, Kathryn I et al. (2017) Subtle hippocampal deformities in breast cancer survivors with reduced episodic memory and self-reported cognitive concerns. Neuroimage Clin 14:685-691
Lampe, Johanna W; Huang, Ying; Neuhouser, Marian L et al. (2017) Dietary biomarker evaluation in a controlled feeding study in women from the Women's Health Initiative cohort. Am J Clin Nutr 105:466-475
Ichikawa, Yuichi; Connelly, Caitlin F; Appleboim, Alon et al. (2017) A synthetic biology approach to probing nucleosome symmetry. Elife 6:
Zhou, Qiyuan; Dai, Jingbo; Chen, Tianji et al. (2017) Downregulation of PKC?/Pard3/Pard6b is responsible for lung adenocarcinoma cell EMT and invasion. Cell Signal 38:49-59
Park, Jong Kook; Peng, Han; Yang, Wending et al. (2017) miR-184 exhibits angiostatic properties via regulation of Akt and VEGF signaling pathways. FASEB J 31:256-265
Raji, Idris; Yadudu, Fatima; Janeira, Emily et al. (2017) Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase. Bioorg Med Chem 25:1202-1218

Showing the most recent 10 out of 1878 publications